Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To analyze the quality of life (QoL), work productivity and activity impairment (WPAI) and healthcare resource utilization (HCRU) in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients receiving golimumab under routine clinical settings in Germany. Materials & methods: Prospective observational study, GO-ART, analyzed changes in WPAI, QoL and HCRU during 24 months of golimumab therapy. Results: Seven hundred and forty-eight patients (RA = 250, PsA = 249 and AS = 249) were enrolled. Substantial improvements in WPAI scores presenteeism, activity impairment and total work productivity impairment and QoL were observed at month three and were maintained through month 24. Fewer patients had disease-related hospitalizations and consulted physician at month 24 than at the baseline. Conclusion: Golimumab induces sustained improvements in WPAI and QoL and reduces healthcare resource utilization in RA, PsA and AS.
Supplementary Material
File (suppl_data.zip)
- Download
- 376.94 KB
References
1.
Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res. Ther. 13(Suppl. 1), S4 (2011).
2.
Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J. Rheumatol. 43(1), 88–96 (2016).
3.
Claudepierre P, van den Bosch F, Sarzi-Puttini P, Vastesaeger N, Govoni M, Kachroo S. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. Int. J. Rheum. Dis. 22(6), 995–1001 (2019).
4.
Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J. Rheumatol. 37(2), 385–392 (2010).
5.
Nakagawa H, Tanaka Y, Sano S et al. Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis. Adv. Ther. 36(3), 691–707 (2019).
6.
Takeuchi T, Nakajima R, Komatsu S et al. Impact of adalimumab on work productivity and activity impairment in japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study. Adv. Ther. 34(3), 686–702 (2017).
7.
Dejaco C, Mueller T, Zamani O et al. FRI0108 Golimumab improves work productivity and activity and quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PSA) and axial spondyloarthritis (AXSPA): interim results from a non-interventional study in austria (go active). Ann. Rheumatic Dis. 77(Suppl. 2), 598–599 (2018).
8.
Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann. Rheum. Dis. 68(6), 789–796 (2009).
9.
Kavanaugh A, Mcinnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60(4), 976–986 (2009).
10.
Inman RD, Davis JC Jr, Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum. 58(11), 3402–3412 (2008).
11.
Scrivo R, Giardino AM, Salvarani C et al. An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. Clin. Exp. Rheumatol. 38(1), 107–114 (2020).
12.
Kruger K, Burmester GR, Wassenberg S, Bohl-Buhler M, Thomas MH. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 8(6), e021082 (2018).
13.
Marra CA, Woolcott JC, Kopec JA et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60(7), 1571–1582 (2005).
14.
Davis JC Jr, Revicki D, van der Heijde DM et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 57(6), 1050–1057 (2007).
15.
Hone D, Cheng A, Watson C et al. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res. (Hoboken) 65(10), 1564–1572 (2013).
16.
Kimball AB, Yu AP, Signorovitch J et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J. Am. Acad. Dermatol. 66(2), e67–e76 (2012).
17.
Chen KC, Wu CH, Tang CH, Huang KC. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: a 1-year mirror-image study using a national claims database. PLoS ONE 13(7), e0200758 (2018).
18.
Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS. Cost–effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur. J. Health Econ. 13(6), 801–809 (2012).
19.
Borse RH, Brown C, Muszbek N, Chaudhary MA, Kachroo S. Cost–effectiveness of golimumab in ankylosing spondylitis from the UK payer perspective. Rheumatol. Ther. 4(2), 427–443 (2017).
20.
Luttropp K, Dozier M, Justo N et al. Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review. BMJ Open 9(5), e027456 (2019).
Information & Authors
Information
Published In
Pages: 891 - 902
PubMed: 32722921
Copyright
© 2020 Merck Sharp & Dahme Corp., a subsidiary of Merck & Co., lnc.,. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 26 May 2020
Accepted: 6 July 2020
Published online: 29 July 2020
Keywords:
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0092
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Juan Luis Sánchez Sevila, José Rosas, José María Ramada Rodilla, Mar Seguí-Crespo, Self-Perceived Difficulty in Job Performance by Working Patients with Uveitis: Global Assessment and by Subscales of Work Demands, Ocular Immunology and Inflammation, 10.1080/09273948.2024.2415539, 33, 3, (423-431), (2024).
- Murray W. Enns, Charles N. Bernstein, Lesley Graff, Lisa M. Lix, Carol A. Hitchon, John D. Fisk, Brenden Dufault, Ruth Ann Marrie, A longitudinal study of distress symptoms and work impairment in immune-mediated inflammatory diseases, Journal of Psychosomatic Research, 10.1016/j.jpsychores.2023.111473, 174, (111473), (2023).
- Panagiotis Athanassiou, Dimitrios Psaltis, Athanasios Georgiadis, Gkikas Katsifis, Athina Theodoridou, Souzana Gazi, Prodromos Sidiropoulos, Maria G. Tektonidou, Andreas Bounas, Anna Kandyli, Periklis Vounotrypidis, Grigorios T. Sakellariou, Dimitrios Vassilopoulos, Zhiping Huang, Evangelia Petrikkou, Dimitrios Boumpas, Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study, Rheumatology International, 10.1007/s00296-023-05376-5, 43, 10, (1871-1883), (2023).
- Christian Dejaco, Thomas Mueller, Omid Zamani, Ulrike Kurtz, Stefan Egger, Johannes Resch-Passini, Anna Totzauer, Babak Yazdani-Biuki, Thomas Schwingenschloegl, Peter Peichl, Angelika Kraus, Gerhard W. Naerr, A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study, Frontiers in Medicine, 10.3389/fmed.2022.881943, 9, (2022).
- Philipp Sewerin, Kathrin Borchert, Dominic Meise, Matthias Schneider, Jörg Mahlich, Health Resource Utilization and Associated Health Care Costs of Biologic Disease‐Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis , Arthritis Care & Research, 10.1002/acr.24598, 74, 9, (1435-1443), (2022).
- Dimitrios Psaltis, Loukas Settas, Athanasios Georgiadis, Eftichia Koukli, Andreas Bounas, Achilleas Livieratos, Evangelia Petrikkou, Heleni Kalogiannaki, Argyro Repa, Dimitrios Vassilopoulos, Prodromos Sidiropoulos, The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study, Rheumatology International, 10.1007/s00296-021-05073-1, 42, 4, (639-650), (2022).
- Panagiotis Athanassiou, Anastasios Kotrotsios, Ioannis Kallitsakis, Andreas Bounas, Theodoros Dimitroulas, Alexandros Garyfallos, Maria G. Tektonidou, Giorgos Vosvotekas, Achilleas Livieratos, Evangelia Petrikkou, Gkikas Katsifis, The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study, Quality of Life Research, 10.1007/s11136-021-03044-4, 31, 5, (1385-1399), (2021).